Biologic Therapy of Leukemia

  • Matt Kalaycio

Part of the Contemporary Hematology book series (CH)

Table of contents

  1. Front Matter
    Pages i-xii
  2. Immunotherapy

    1. Front Matter
      Pages 1-1
    2. Brian J. Bolwell
      Pages 13-27
    3. Matt Kalaycio
      Pages 29-42
    4. Arthur E. Frankel, Bayard L. Powell, Eli Estey, Martin S. Tallman
      Pages 43-58
    5. John M. Burke, Joseph G. Jurcic
      Pages 59-77
  3. Cytokines

    1. Front Matter
      Pages 79-79
    2. Thomas Fischer
      Pages 81-91
    3. Peter Kabos, Gary J. Schiller
      Pages 93-105
  4. Targeted Therapeutics

    1. Front Matter
      Pages 107-107
    2. Stanley R. Frankel
      Pages 109-126
    3. Michael E. O’Dwyer, Brian J. Druker
      Pages 127-144
    4. Thomas R. Chauncey
      Pages 145-162
    5. Benjamin M. F. Mow, Scott H. Kaufmann
      Pages 163-186
  5. Differentiation Agents

    1. Front Matter
      Pages 187-187
    2. Chadi Nabhan, Martin S. Tallman
      Pages 189-203
  6. Gene Therapy

    1. Front Matter
      Pages 223-223
    2. Paul J. Orchard, R. Scott Mclvor
      Pages 225-259
  7. Back Matter
    Pages 261-269

About this book


Exciting new "biologic" therapies for treating leukemia are appearing so rapidly that clinicians often find it difficult to make informed decisions about their use when making patient treatment decisions. In Biologic Therapy of Leukemia, distinguished physicians and medical researchers summarize and review all the available data concerning these cutting-edge biologic therapies so that practicing clinicians can make correct patient-care choices. Here the busy physician will find, in one convenient place, crucial information on the uses and limitations of the major biologic therapies for leukemia, the different biologic strategies for its treatment, the management of patients being treated with such biologic agents, and the current and future role of emerging biologic agents. Well-established therapies, such as interferon and all-trans-retinoic acid, are included so that their efficacy can be contrasted with such newer agents as imatinib mesylate and arsenic trioxide. P-glycoprotein inhibitors, interleukins, and the graft-vs-leukemia effect are also examined, along with approaches that reverse failure of apoptosis, alter genetic codes, and modulate immunologic mechanisms.
Authoritative and readily accessible, Biologic Therapy of Leukemia provides today's practicing oncologists with a comprehensive review of all currently available biologic approaches and agents, as well as the many different subtypes of leukemia, affording expert guidance in choosing optimal therapies for each patient.


antibody cytokine cytokines dendritic cells gene gene therapy immunotherapy interferon leukemia management patients protein signal transduction therapy treatment

Editors and affiliations

  • Matt Kalaycio
    • 1
  1. 1.Leukemia Program, Department of Hematology and Medical OncologyCleveland Clinic FoundationClevelandUSA

Bibliographic information

Industry Sectors